FORMULATION OF POLY HERBAL NOVEL DRUG DELIVERY SYSTEM FOR ANTI RHEUMATOID ARTHRITIS

Novel herbal drug delivery system opens new vistas for delivery of herbal drugs at right place, at right concentration, for right period of time and also gives scientific angle to verify the standardization of herbal drug. Herbal Transdermal patches can develop valuable assessment and drug safety by additional site specific the way and temporal position in the body’s imperative to reduce the number and size of doses required to achieve the objective of systemic medication during topical application to the intact skin surface. Rheumatoid Arthritis (RA) is a chronic, progressive autoimmune disease of unknown cause. It is characterized by persistent inflammation that primarily affects the peripheral joints. In the present study, herbal transdermal patch was developed by using ethanolic extract of leaves of Cardiospermum halicacabum and rhizomes of Drynaria quercifolia that had already been widely used for the treatment of arthritis in conventional dosage forms. Evaluation of the developed patch for the effectiveness against RA was done by in vitro methods in terms of inhibition of albumin denaturation, measurement of Interleukin-6 cytokines by Enzyme-Linked Immuno Assay (ELISA). IC-50 value was determined from albumin denaturation inhibition assay. The herbal patch significantly and dosedependently inhibited Interleukin–6 cytokines. The present study revealed that the formulated polyherbal Transdermal patch will be the better drug of choice for the treatment of Rheumatoid Arthritis as compared to the conventional dosage forms.

FORMULATION AND EVALUATION OF MASLINIC ACID LOADED TRANSDERMAL PATCHES

Objective: To develop and evaluate Transdermal patch of Maslinic acid for Transdermal drug delivery. The current study is to develop Transdermal drug delivery system. Methods: Suitable method such as Solvent Casting Technique of Film Casting Technique are used for preparation of Transdermal patch. Results: The prepared Transdermal patches were transparent, smooth, uniform and flexible. The method adopted for the preparation of the system was found satisfactory. Conclusion: Various formulations were developed by using hydrophilic and hydrophobic polymers like HPMC E5 and EC respectively in single and combinations by solvent evaporation technique with the incorporation of penetration enhancer such as dimethylsulfoxide and dibutyl phthalate as plasticizer In vitro studies concluded that HPMC E5 patches has better release than that of EC patches, which may be attributed to high water vapour permeability of HPMC patches and hydrophobic nature of EC. An attempt was made to incorporate HPMC E5 and EC to the monolithic system for better release and prolong the duration of release. Formulation F7 containing an equal ratio of HPMC E5: EC (5:5) showed maximum and sustained release of 86.816±0.264 within 24 h. Kinetic models were used to confirm the release mechanism of the formulations. Maslinic acid release from the patches F1 to F7 followed non Fickian diffusion rate controlled mechanism.

Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review

Objective: The effects of rotigotine transdermal patch (RTG) on the neuropsychiatric symptoms of Parkinson's disease (PD) outcomes remain controversial. The aim of this review was to determine the efficacy and safety of RTG on the neuropsychiatric symptoms of PD.Methods: In this systematic review and meta-analysis, PubMed, Cochrane Library, EMBASE, and Web of Science were searched for randomized controlled trials comparing RTG and placebo in PD up to May 10, 2021. We analyzed the data using Review Manager 5.2 software. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation Approach. In order to avoid false-positive results caused by random error, we use TSA software for trial sequential analysis (TSA).Results: We included 10 studies (1,844 patients). The meta-analysis showed that, compared with placebo, RTG can significantly improve the scores for Apathy Scale (MD = −1.68, 95% confidence interval, CI: −2.74 to −0.62, P = 0.002; moderate certainty), Beck Depression Inventory-II (MD = −1.19, 95% CI: −2.26 to −0.11, P = 0.03; moderate certainty), the Non-Motor Symptoms Scale (MD = −3. 66, 95% CI: −4. 30 to −3.01, P < 0.00001; moderate certainty), the sleep/fatigue domains of the Parkinson's Disease Non-motor Symptom Assessment Scale (MD = −2.03, 95% CI: −3.08 to −0.98, P = 0.0001; moderate certainty), the mood/apathy domains of the Non-motor Symptom Scale (MD = −2.48, 95% CI: −4.07 to −0.89, P = 0.002; high certainty), the eight-item Parkinson's Disease Questionnaire (MD = −4. 93, 95% CI: −6.79 to −3.07, P < 0.00001; moderate certainty), and the 39-item Parkinson's Disease Questionnaire (MD = −3.52, 95% CI: −5.25 to −1.79, P < 0.0001; high certainty). However, there was no statistically significant difference on the Snaith–Hamilton Pleasure Scale (MD = −0.12, 95% CI: −0.58 to 0.34, P = 0.61). Our results showed that RTG exerts a positive effect on sleep. According to the TSA, the results implied that, except for the Beck Depression Inventory-II, conclusive evidence have been obtained in the RTG group. It has been proven in our meta-analysis that rotigotine has good safety and tolerability.Conclusions: RTG can effectively improve the neuropsychiatric symptoms, sleep quality, and quality of life in patients with PD.

Development and Evaluation of Flupirtine Maleate Transdermal Patch Containing Different Permeation Enhancers

The present study was aimed at the formulation of transdermal patches of flupirtine maleate containing different permeation enhancers. It acts indirectly as N-methyl-D-aspartate (NMDA) receptor antagonist and activates the K+ channels; thereby acts as a skeletal muscle relaxant. Flupirtine maleate transdermal patches are intended to provide localized effect. The patches were prepared by solvent evaporation technique, using polyvinyl alcohol (PVA) as the polymer whereas dimethyl sulfoxide (DMSO) and polyethylene glycol (PEG-400) as the permeation enhancers. Methanol was used as a solvent to dissolve the drug and glycerol was used as the plasticizer. These patches were evaluated for in vitro permeation, tensile strength, percent moisture absorption, drug content uniformity, film thickness, weight variation and folding endurance. All the patches showed extended release properties. Formulation FDD8 containing 8% polymer and 2% DMSO was found to be the optimized formulation on the basis of evaluation parameters. In vitro permeation release was found to be 95.71 ± 0.01% at the end of 12 h. As the concentration of DMSO increased, the release profile of drug was enhanced. This indicated that DMSO improved the release profile of flupirtine maleate when compared to PEG-400. The release kinetics of the transdermal patches followed Higuchi matrix model. The stability studies showed that all the optimized patches were stable during their study period. From the present study, it can be concluded that addition of DMSO yields good result to enhance the permeation of the drug. Keywords: flupirtine maleate, transdermal patch, permeation enhancers, dimethyl sulfoxide DMSO, polyethylene glycol PEG-400, polyvinyl alcohol PVA.